Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

Indy Hematology Review 2025: State of the Art 2025 - Emerging Therap…

Indy Hematology Review 2025

R. Birhiray

ASH 2024 Summary: Highlights in Adult ALL and Implications for Pract…

2024 ASH Annual Meeting Insights Hub

R. Cassaday

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Steroid-Refractory GVHD Updates

Roswell Park Comprehensive Cancer Center

S. Holtan

ASH 2024 Summary: Highlights in Ph- ALL

2024 ASH Annual Meeting Insights Hub

F. Haddad

Indy Hematology Review 2025: Experts Debate the Treatment of ALL in …

Indy Hematology Review 2025

R. Stone

Revumenib for KMT2A+ R/R Acute Leukemias - Drug Overview and Clinica…

OncoPharm

J. Bossaer

The Role of Blinatumomab in Frontline B-ALL Treatment

Mark Litzow

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

ASH 2024 Summary: Highlights in Ph+ ALL

2024 ASH Annual Meeting Insights Hub

F. Haddad

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Best Practices in Blinatumomab Use for B-Cell ALL: Insights from Cli…

City of Hope

V. Pullarkat

Tandem 2025 Insights: PTCy-Based GVHD Prophylaxis After Mismatched U…

Insights from 2025 Tandem Annual Meeting

M. Al Malki

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

Sarah Tasian

ASH 2024 Insights: COG AALL1731 - Blinatumomab Added to Chemo in New…

2024 ASH Annual Meeting Insights Hub

S. Gupta

Infectious Disease Perspective of CAR T-Cell Therapy

Moffitt Cancer Center

A. Baluch